FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Pfizer | Lipitor | Pharma buyout | Sanofi-Aventis

Pfizer-Sanofi match not made in heaven?

Tools

Say the Pfizer/Sanofi-Aventis rumors are true: Would merging with the French drug maker boost Pfizer's fortunes? Not so much, say some observers.

The two companies do have some strengths in common--particularly their cardiovascular and central nervous system products. But they also share weaknesses. Some of their major patents would expire in tandem, for instance; Pfizer's blockbuster Lipitor goes off patent in 2012, and 2011 is D-Day for Sanofi-Aventis' Plavix (which it markets along with Bristol-Myers Squibb). So they also share a need for new big-selling products. And really--would the French easily relinquish one of their business jewels to American sway?

- read the Dow Jones column

Related Articles:
Sanofi stock up on Pfizer buyout talk. Report
Pfizer, Wyeth merger bad idea? Report

Read more on: Pfizer | Sanofi-Aventis

More stories about Pfizer   Lipitor   Pharma buyout   Sanofi-Aventis  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.